The intravenous route is not FDA approved and is generally not recommended except when no other alternatives are available. Intravenous administration appears to be associated with a higher risk of QT prolongation and torsade de pointes (TdP) than other forms of administration. The manufacturer recommends ECG monitoring for QT prolongation and arrhythmias if IV administration is required. A dose in the range of 1 to 5 mg IV has been suggested, with the dose being repeated at 30 to 60 minute intervals, if needed. A maximum IV dose has not been established. The lowest effective dose should be used in conjunction with conversion to oral therapy as soon as possible.
Common adverse effects of Haldol usually include sleepiness, dizziness, rapid heart beat, constipation, excess saliva production and weight gain. Another important adverse effect that occurs commonly is orthostatic hypotension (a lowering of your blood pressure when you are sitting up or standing up). Occasionally this can lead to fainting and falling down, therefore, people taking Haldol should be careful when they change positions. These adverse effects are usually mild and usually go away after the first several days of starting treatment or increasing a dose.
Manus Aktteva Biopharma LLP, an ISO 9001: 2008 certified sourcing & export concern takes pride in fulfilling your requirements of Nutraceuticals, Specialty Chemicals, Pharmaceutical APIs and their advance level intermediates from ISO Certified, GMP, CGMP & USFDA approved units with supportive regulatory documentations like DMF, EDMF, COS, USDMF etc. We wish to state that anyone interested in sourcing any special molecules, APIs, Intermediates, Chiral Compounds etc. and feels it is difficult for early completion of tasks, please call on us and TEST US TO GET THE BEST OF US.